FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHA	NGES IN E	BENEFICIAL	OWNERSHIP

	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burde	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Mullennix Stephen					2. Issuer Name and Ticker or Trading Symbol UroGen Pharma Ltd. [URGN]								heck all ap Dire V Offic	ctor er (give title	ng Pers	10% Ov Other (s	/ner			
(Last) (First) (Middle) C/O UROGEN PHARMA LTD. 499 PARK AVENUE						3. Date of Earliest Transaction (Month/Day/Year) 01/26/2020									A below) below) Chief Operating Officer					
(Street) NEW YOU CITY	ORK N	Y	10022		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City)	(S	-	(Zip)																	
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac Date (Month/Da			action	ction 2A. Deemed Execution Date,		3. Transa	Transaction Disposed Of (D) (Instr. 3, 4			ed (A) or	or 5. Amount of and Securities		Form: Direct	7. Nature of Indirect						
			(Month/l	Day/Yea			Day/Yea	Code (I 8)	v	5) Amount	unt (A) or Pr		Repor Trans	l Following	(D) or (I) (Ins	str. 4) (Beneficial Ownership (Instr. 4)			
Ordinary Shares 01/26/				6/2020	2020		М		1,666	- 1 .	(1)	<u> </u>	9,349		D					
Ordinary Shares 01/27/2			7/2020	/2020		S		684 ⁽²⁾ D		\$29.	26 8,665			D						
		Т							uired, D s, option					y Owned	l					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/Da	Date,		ansaction ode (Instr.		n of l		6. Date Exercisal Expiration Date (Month/Day/Year)		Amount of		8. Price o Derivative Security (Instr. 5)		i (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				c	Code	v	(A)	(D)	Date Exercisab		expiration vate	Title	Amount or Number of Shares							
Restricted Stock Units	(1)	01/26/2020			M			1,666	(3)		(3)	Ordinary Shares	1,666	\$0.00	3,334		D			

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
- 2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
- 3. The reporting person was granted 5,000 Restricted Stock Units ("RSUs") on January 26, 2019. 33.33% of the RSUs vested on January 26, 2020 and 12.5% of the remaining RSUs will vest in eight equal quarterly installments thereafter.

Remarks:

/s/ Peter Pfreundschuh, 01/28/2020 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.